Abstract

BackgroundHigh expression of the receptor tyrosine kinase Axl is associated with poor prognosis in patients with Renal Cell Carcinoma (RCC), the most common malignancy of the kidney. The miR-34a has been shown to directly regulate Axl in cancer cells. The miR-34a is a mediator of p53-dependent tumor suppression, and low expression of miR-34a has been associated with worse prognosis in several cancers. Our aim was to elucidate whether miR-34a or the other members of the miR-34 family (miR-34b/c) regulate Axl in RCC.Methodology and ResultsUsing western blot, flow cytometry, and RT-qPCR, we showed that Axl mRNA and protein are downregulated in 786-O cells by miR-34a and miR-34c but not by miR-34b. A luciferase reporter assay demonstrated direct interaction between the Axl 3’ UTR and miR-34a and miR-34c. The levels of miR-34a/b/c were measured in tumor tissue in a cohort of 198 RCC patients, and the levels of miR-34a were found to be upregulated in clear cell RCC (ccRCC) tumors, but not associated with patient outcome. Neither of the miR-34 family members correlated with Axl mRNA, soluble Axl protein in serum, nor with immunohistochemistry of Axl in tumor tissue. In addition, we measured mRNA levels of a known miR-34a target, HNF4A, and found the HNF4A levels to be decreased in ccRCC tumors, but unexpectedly correlated positively rather than negatively with miR-34a.ConclusionsAlthough miR-34a and miR-34c can regulate Axl expression in vitro, our data indicates that the miR-34 family members are not the primary regulators of Axl expression in RCC.

Highlights

  • Renal Cell Carcinoma (RCC) is the most common malignancy of the kidney, causing approximately 85% of all kidney tumors [1]

  • Flow cytometry, and room temperature (RT)-qPCR, we showed that Axl mRNA and protein are downregulated in 786-O cells by miR-34a and miR-34c but not by miR-34b

  • The levels of miR-34a/b/c were measured in tumor tissue in a cohort of 198 RCC patients, and the levels of miR-34a were found to be upregulated in clear cell RCC tumors, but not associated with patient outcome

Read more

Summary

Introduction

Renal Cell Carcinoma (RCC) is the most common malignancy of the kidney, causing approximately 85% of all kidney tumors [1]. While RCC patients diagnosed with localized disease have a 5-year survival of 69% [1], the 5-year survival for patients with metastatic RCC is approximately 10 to 12%; the main reason for the poor prognosis in the latter is acquired resistance to targeted therapies [2, 4, 5]. Axl is reported to be overexpressed in a number of malignancies [8, 9], including RCC where it has been shown to predict patient outcome [10, 11]. High expression of the receptor tyrosine kinase Axl is associated with poor prognosis in patients with Renal Cell Carcinoma (RCC), the most common malignancy of the kidney. Our aim was to elucidate whether miR34a or the other members of the miR-34 family (miR-34b/c) regulate Axl in RCC

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call